Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The maximum days the report can be obtained for the test CLL Prognostication/Risk Stratification Gene Panel is 14 days.

What are the prerequisites for the test CLL Prognostication/Risk Stratification Gene Panel

  • Patient must have a diagnosis of Chronic Lymphocytic Leukemia (CLL)
  • Physician must order the test
  • Specimen must be collected and sent to the laboratory
  • Patient must provide consent for genetic testing

What are the measure values for the test CLL Prognostication/Risk Stratification Gene Panel

  • IGHV Mutation Status
  • ZAP-70 Expression
  • CD38 Expression
  • Del(17p)
  • Del(11q)
  • Trisomy 12
  • Del(13q)

What does this test CLL Prognostication/Risk Stratification Gene Panel identify?

  • Identification of TP53 mutations, which are associated with poor prognosis in CLL
  • Detection of NOTCH1 mutations, which have been linked to aggressive disease and resistance to treatment
  • Analysis of SF3B1 mutations, which are associated with a favorable prognosis in CLL
  • Evaluation of IGHV mutation status, which can help predict disease progression and response to therapy
  • Assessment of ZAP70 and CD38 expression levels, which are markers of disease aggressiveness

Why is this test CLL Prognostication/Risk Stratification Gene Panel taken?

CLL Prognostication/Risk Stratification Gene Panel Test

The CLL Prognostication/Risk Stratification Gene Panel test is taken to assess the prognosis and risk stratification for patients with Chronic Lymphocytic Leukemia (CLL). This test analyzes specific genetic markers and mutations that can provide valuable information about the aggressiveness of the disease, likelihood of progression, and potential response to treatment.

By identifying these genetic factors, healthcare providers can tailor treatment plans to individual patients, helping to optimize outcomes and improve overall survival rates. The results of this test can also help guide decisions regarding the intensity and duration of therapy, as well as the need for close monitoring and follow-up.

Overall, the CLL Prognostication/Risk Stratification Gene Panel test plays a crucial role in personalized medicine, allowing for more targeted and effective management of CLL based on each patient's unique genetic profile.

No FAQs available.

Customer Google Rating